Dr Lewis Au
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
65 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
DOI: 10.1016/j.eururo.2026.03.0242026
Journal article
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.
DOI: 10.1038/s41467-026-74076-y2026
Journal article
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.
DOI: 10.2967/jnumed.126.2720852026
Journal article
A phase 1/2 study to assess peptidomimetic carbonic anhydrase IX imaging and therapy with [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in patients with advanced clear cell renal cell carcinoma and other solid tumors.
DOI: 10.1200/JCO.2026.44.7_suppl.TPS5692026
Journal article
Retraction note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy (Nature, (2023), 616, 7957, (563-573), 10.1038/s41586-023-05771-9)
DOI: 10.1038/s41586-026-10104-72026
Journal article
Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications
DOI: 10.3390/cancers180201952026
Journal article
Beyond the Primary Tumour: Rethinking Biomarker Strategies in Recurrent Renal Cell Carcinoma
DOI: 10.1016/j.eururo.2026.06.003
RECENT SCHOLARLY WORKS
2025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Journal article
Neoadjuvant Pembrolizumab and Stereotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER): A Phase II Randomised Clinical Trial
DOI: 10.1016/j.ijrobp.2025.06.11782025
Conference Proceedings
2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
DOI: 10.1016/j.annonc.2025.08.3002